1-氨基-1-丙基环己烷 | 68288-34-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 1-氨基-1-丙基环己烷
• 英文名称: 1-propyl-cyclohexylamine
• 英文别名: 1-Propyl-cyclohexylamin；1-propylcyclohexanamine；1-Amino-1-propylcyclohexane；1-propylcyclohexan-1-amine
• CAS: 68288-34-6
• 化学式: C₉H₁₉N
• 分子量: 141.257
• InChiKey: STPFBIXYQQWASO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-溴丁酸乙酯 、 1-氨基-1-丙基环己烷 、 4-氯苯甲酰氯 生成 N-(p-chloro)benzoyl-4-[(1-propylcyclohexyl-1)-amino]butyric acid
  参考文献：
  名称：

  DE2856722

  摘要：

  公开号：
• 作为产物：
  描述：

  1-propyl-cyclohexanecarboxylic acid amide 在 氢氧化钾 、 次溴酸钾 作用下， 生成 1-氨基-1-丙基环己烷
  参考文献：
  名称：

  The Synthesis of Some Teritary Carbinamines as Vasopressor Agents

  摘要：

  DOI：

  10.1021/ja01098a033

文献信息

• [EN] INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE<br/>[FR] INHIBITEURS DE L'INDOLÉAMINE 2,3-DIOXYGÉNASE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2020023355A1

  公开（公告）日：2020-01-30

  The present invention provides compounds of formula (I): wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases.

  本发明提供了以下化合物（I）的公式：其中所有变量如本文所定义。这些化合物是色氨酸2,3-二氧化酶（IDO）的抑制剂，可用作治疗增殖性疾病，如癌症、病毒感染和/或自身免疫疾病的药物。
• Heteroatom bridged metallocene compounds for olefin polymerization
  申请人：Voskoboynikov Z. Alexander

  公开号：US20070135597A1

  公开（公告）日：2007-06-14

  This invention relates to a transition metal compound represented by the formula: wherein M is a group 3, 4, 5 or 6 transition metal atom, or a lanthanide metal atom, or actinide metal atom; E is: 1) a substituted or unsubstituted indenyl ligand that is bonded to Y through the four, five, six or seven position of the indenyl ring, or 2) a substituted or unsubstituted heteroindenyl ligand that is bonded to Y through the four, five or six position of the heteroindenyl ring, provided that the bonding position is not the same as the position of the ring heteroatom, or 3) a substituted or unsubstituted fluorenyl ligand that is bonded to Y through the one, two, three, four, five, six, seven or eight position of the fluorenyl ring, or 4) a substituted or unsubstituted heterofluorenyl ligand that is bonded to Y through the one, two, three, four, five or six position of the heteroindenyl ring, provided that the bonding position is not the same as the position of the ring heteroatom; A is a substituted or unsubstituted cyclopentadienyl ligand, a substituted or unsubstituted heterocyclopentadienyl ligand, a substituted or unsubstituted indenyl ligand, a substituted or unsubstituted heteroindenyl ligand, a substituted or unsubstituted fluorenyl ligand, a substituted or unsubstituted heterofluorenyl ligand, or other mono-anionic ligand; Y is a Group 15 or 16 bridging heteroatom substituent that is bonded via the heteroatom to E and A; and X are, independently, univalent anionic ligands, or both X are joined and bound to the metal atom to form a metallocycle ring, or both X join to form a chelating ligand, a diene ligand, or an alkylidene ligand. This invention further relates to catalyst systems comprising the above transiotioon metal compounds, activators and optional supports and their use to polymerize or oligomerize olefins.

  本发明涉及一种过渡金属化合物，其表示为以下公式：其中M是3、4、5或6族过渡金属原子，或镧系金属原子，或锕系金属原子；E是：1）与Y通过茚环的四、五、六或七位置结合的取代或未取代的茚基配体，或2）与Y通过杂环茚环的四、五或六位置结合的取代或未取代的杂环茚基配体，前提是结合位置与环杂原子的位置不同，或3）与Y通过芴环的一、二、三、四、五、六、七或八位置结合的取代或未取代的芴基配体，或4）与Y通过杂芴环的一、二、三、四、五或六位置结合的取代或未取代的杂芴基配体，前提是结合位置与环杂原子的位置不同；A是取代或未取代的环戊二烯基配体，取代或未取代的杂环戊二烯基配体，取代或未取代的茚基配体，取代或未取代的杂环茚基配体，取代或未取代的芴基配体，取代或未取代的杂芴基配体，或其他单阴离子配体；Y是通过杂原子与E和A结合的15族或16族桥接杂原子取代基；X是独立的一价阴离子配体，或两个X结合并与金属原子结合形成金属环，或两个X结合形成螯合配体、二烯基配体或烷基亚基配体。本发明还涉及包含上述过渡金属化合物、活化剂和可选支撑物的催化剂系统及其用于聚合或寡聚烯烃的用途。
• Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
  申请人：——

  公开号：US20040087658A1

  公开（公告）日：2004-05-06

  The invention relates to a novel drug combination therapy useful in the treatment of dementia comprising administering an 1-aminocyclohexane derivative such as memantine or neramexane and an acetylcholinesterase inhibitor (AChEI) such as galantamine, tacrine, donepezil, or rivastigmine.

  该发明涉及一种新型药物组合疗法，可用于治疗痴呆，包括给予一种1-氨基环己烷衍生物，如美万特或奈拉美喜，以及一种乙酰胆碱酯酶抑制剂（AChEI），如加兰他明、他克林、多奈哌齐或利伐替明。
• METHODS OF TREATING CNS DISORDERS
  申请人：PAPADAKIS Kelly

  公开号：US20090275597A1

  公开（公告）日：2009-11-05

  The present invention relates to methods of treating various CNS disorders, e.g., mania, bipolar disorder and schizophrenia, by administering NMDA receptor antagonists, alone or in combination with dopamine receptor antagonists.

  本发明涉及治疗各种中枢神经系统疾病的方法，例如躁狂症、双相情感障碍和精神分裂症，通过单独或与多巴胺受体拮抗剂联合给予NMDA受体拮抗剂。
• [EN] THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC Aß PEPTIDES IN AMYLOIDOPATHIES<br/>[FR] UTILISATION DE DERIVES DE 1-AMINOCYCLOHEXANE POUR MODIFIER LE DEPOT DE PEPTIDES A DOLLAR G(B) FIBRILLOGENES DANS DES AMYLOIDOPATHIES
  申请人：MERZ PHARMA GMBH & CO KGAA

  公开号：WO2005079779A1

  公开（公告）日：2005-09-01

  The invention relates to the use of NMDA receptor antagonists such as 1-aminocyclohexane derivatives to modify deposition of potentially toxic and fibrillogenic Aß peptides in amyloidopathies. Specifically, the invention relates to the ability of memantine to intervene in the processing of APP and decrease the levels of fibrillogenic Aß peptides.

  本发明涉及使用NMDA受体拮抗剂，如1-氨基环己烷衍生物，以改变淀粉样病变中潜在有毒和纤维化Aß肽的沉积。具体而言，本发明涉及美金刚烷干预APP处理并降低纤维化Aß肽水平的能力。